Table 1.
Clinical characteristics of the three disease group.
| GRS cohort (N = 9) | Non-GRS cohort (N = 8) | iTLE cohort (N = 7) | |
|---|---|---|---|
|
| |||
| Mean age, yrs. (Range) | 50 (32–57) | 56 (28–74) | 46 (26–74) |
| Sex (n) | Male (8): Female (1) | Male (6): Female (2) | Male (2): Female (5) |
| Presenting symptom (n) | Seizure (9) | Incidental (1), Hearing problem (1), Headache (1), Dysphasia (2), Memory, complaint (2), Syncope (1) | Seizure (7) |
| Disease duration (mean) | 4.5 months | 4.7 months | 191 months |
| Focal aware (3) | Focal impaired aware (7) | ||
| Seizure type (n) | Focal impaired aware (4) | N/A | Focal to bilateral tonic-clonic (4) |
| Focal to bilateral tonic-clonic (3) | |||
| Antiseizure drug therapy (n) | Levetiracetam (7), Lamotrigine (1), Lacosamide (1), Zonisamide (1) | None (7) | Lamotrigine (2), Levetiracetam (4) Lacosamide (1), Topiramate (2) Perampanel (1), Clobazam (1), Eslicarbazepine (1) |
| Resected tissue location (side, lobe) [n] | Left frontal (3), left temporal (2), right temporal (3), left parietal (1) | Levetiracetam (1) | Right temporal (5) |
| Left temporal (2) | |||
| Pathology (n) | Diffuse astrocytoma, IDH1 mutant (1) | Right frontal (1), left frontal (1), left temporal (2), right temporal (1), left parietal (3) | Mild gliosis (2) |
| Oligodendroglioma IDH1 mutant, 1p/19q co-deleted (3) | Marked gliosis (2) | ||
| Anaplastic astrocytoma, IDH1 wild (3) | Chaslin gliosis (3) | ||
| Glioblastoma, IDH1 wild, MGMT-(2) | |||
GRS: glioma-related seizure; iTLE: idiopathic temporal lobe epilepsy; NA: not applicable; IDH1: isocitrate dehydrogenase 1; MGMT+: O6-methylguanine-DNA methyl-transferase- gene promoter methylation; MGMT-: MGMT gene promotor un- methylated.